Virax Biolabs Group (NASDAQ:VRAX) experienced a dramatic surge in its stock price on Thursday, jumping 183% during U.S. trading hours. The rally followed the announcement that the company's UK subsidiary had entered into an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune-profiling product line. As of 11:52 a.m. EDT, shares were trading at $9.00, up $5.82, with approximately 57.8 million shares changing hands.
Deal Details and Market Reach
The agreement grants Fosun Diagnostics exclusive rights to distribute ImmuneSelect across six key Southeast Asian markets: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. Supply is expected to commence once purchase orders are placed. The deal also includes provisions for potential expansion into larger or private-label orders, offering a pathway for scaling commercial activity in the region.
Product Positioning and Differentiation
ImmuneSelect is classified as a research-use-only (RUO) product, meaning it is intended solely for laboratory research and not for diagnostic or therapeutic applications. Virax emphasized that ImmuneSelect is distinct from its ViraxImmune diagnostic platform, which remains under development and is undergoing clinical and regulatory evaluations. The ImmuneSelect line includes ELISpot testing plates, which enable laboratories to monitor cellular immune response activity.
Financial Context and Strategic Shift
The sharp price increase comes from a low base, as Virax reported minimal revenue of just $12,423 for the fiscal year ended March 31, 2026, entirely from RUO products, alongside a net loss of approximately $5.0 million. The company is pursuing a strategic transition from a small research-products supplier to a commercial player. Chief Executive James Foster described the Fosun deal as a "major step forward" that provides a "clear pathway" for regional growth. Leon Zhang, head of China domestic business for Fosun MedTech, noted that Fosun is exploring ELISpot-based research applications and called Virax's platform a "strong option."
Competitive Landscape and Risks
Virax faces competition from established players in immune profiling, research reagents, and in vitro diagnostics, including QIAGEN (QGEN), Adaptive Biotechnologies (ADPT), and Abbott Laboratories (ABT). The company acknowledges that many competitors possess larger sales teams, broader product portfolios, and more robust regulatory infrastructures. Virax also cautioned that the Fosun deal may not necessarily translate into revenue or commercial progress, as studies or regulatory steps could fall short of requirements for filing, launching, or product adoption.
Market Performance and Technical Context
The rally occurred less than two weeks after Virax executed a one-for-25 reverse stock split on June 26 to comply with Nasdaq's minimum $1 bid price requirement. The reverse split raised the per-share price but did not alter overall shareholder equity. Despite the surge, the company's market capitalization remains modest at approximately $21.6 million. Investors are now focused on seeing actual purchase orders, sustained demand from Thailand, and evidence that Fosun can effectively introduce the product into the other five markets outlined in the agreement.
Fosun's Background
Fosun Diagnostics operates as the diagnostics segment of Fosun MedTech, which is part of Fosun Pharma, a company listed on the Shanghai and Hong Kong stock exchanges. Fosun Pharma reported 2025 revenue of RMB 41.662 billion (approximately $5.8 billion).
